Page last updated: 2024-12-07

alpha-peltatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alpha-peltatin is a natural product isolated from the mushroom *Peltandra virginica*. It exhibits potent antitumor activity in vitro and in vivo. The compound has been shown to induce apoptosis in cancer cells and inhibit angiogenesis. Alpha-peltatin is currently being investigated as a potential anticancer agent, but clinical trials are still in their early stages. Research on alpha-peltatin is driven by its potential to provide a novel therapeutic strategy for treating cancer.'

alpha-peltatin: RN given for (5R-(5alpha,5beta,8aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alpha-peltatin : An organic heterotetracyclic compound that is 4'-demethylpodophyllotoxin which is substituted by a hydroxy group at position 10 but which is lacking the hydroxy group at position 9. It is found as a glucoside in the rhizomes of Podophyllum peltatum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PodophyllumgenusA genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.[MeSH]BerberidaceaeThe Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH]

Cross-References

ID SourceID
PubMed CID92129
CHEMBL ID95972
CHEBI ID10324
SCHEMBL ID15220296
MeSH IDM0142498

Synonyms (37)

Synonym
CHEMBL95972
chebi:10324 ,
peltatin, alpha
furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-
.alpha.-peltatin
nsc35463
nsc-35463
naphtho[2,3-dioxole-6-carboxylic acid, 5,6,7,8-tetrahydro-9-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-7-(hydroxymethyl)-, .gamma.-lactone
furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-, [5r-(5.alpha.,5a.beta.,8a.alpha.)]-
peltatin a
NSC24817 ,
nsc-24817
nci-1074
NCI60_001980
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-
nsc 24817
nci 1074
alpha-peltatin a
568-53-6
alpha-peltatin
peltatin-a
(5ar,8ar,9r)-4-hydroxy-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[6,5-f][1,3]benzodioxol-8-one
(5ar,8ar,9r)-4-hydroxy-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
eho76y1jao ,
unii-eho76y1jao
(5r,5ar,8ar)-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
8-hydroxy-2-hydroxymethyl-6,7-methylenedioxy-4-(4'-hydroxy-3',5'-dimethoxyphenyl)-1,2,3,4-tetrahydronaphthalene-3-carboxylic acid lactone
[5r-(5alpha,5aalpha,5abeta,8aalpha)]-5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',3':6,7]naphtho[2,3-d]-1,3-dioxo-6(5ah)-one
SCHEMBL15220296
.alpha.-peltatin [mi]
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5r,5ar,8ar)-
(5r,5ar,8ar)-5,8,8a,9-tetrahydro-10-hydroxy-5-(4-hydroxy-3,5-dimethoxyphenyl)furo(3,4:6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one
.alpha.-peltatin a
DTXSID30205349
Q27108616
PD011321
AKOS040761342
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
furonaphthodioxole
gamma-lactoneA lactone having a five-membered lactone ring.
organic heterotetracyclic compound
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID404066Cytotoxicity against human primary amnion cells assessed as morphological changes by microscopic examination1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID400478Cytotoxicity against african green monkey Vero cells assessed as cell viability at 1 uM by trypan blue exclusion assay
AID400477Cytotoxicity against african green monkey Vero cells assessed as cell rounding at 1 uM
AID403984Therapeutic index, ratio of MTC for human primary amnion cells to lowest drug level causing inhibition of HSV11998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID57216Compound was tested for percentage inhibition against DNA topoisomerase II1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Antitumor agents. 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues.
AID91438Inhibitory activity against 3'-processing by HIV-1 Integrase at 100 uM1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase.
AID221407Compound was tested for Immunosuppression activity by mixed lymphocyte reaction (MLR) in murine splenocytes of mice1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Immunosuppressive cyclolignans.
AID400481Antiviral activity against measles virus infected in african green monkey Vero cells assessed as plaque formation at 1 uM after 5 days by neutral red assay relative to control
AID235867Non cytotoxic IM activity index which is the ratio of IC50 of LcV to IC50 of MLR1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Immunosuppressive cyclolignans.
AID91560Inhibitory activity against strand transfer by HIV-1 Integrase at 100 uM1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
(-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase.
AID403990Antiviral activity against Murine cytomegalovirus in mouse 3T3-L1 cells at 250 nM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID96193Compound was tested for in vitro cytotoxicity in KB cells after 3 days of incubation1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Antitumor agents. 100. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and alpha-peltatin.
AID400482Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as plaque formation at 1 uM after 4 days by neutral red assay relative to control
AID140793Compound was tested for Cytotoxic activity by lymphocyte viability assay.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Immunosuppressive cyclolignans.
AID57206Compound was tested for inhibition against human DNA topoisomerase II1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Antitumor agents. 100. Inhibition of human DNA topoisomerase II by cytotoxic ether and ester derivatives of podophyllotoxin and alpha-peltatin.
AID400480Antiviral activity against measles virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect at 1 uM
AID337695Antibacterial activity against Escherichia coli ATCC 25922 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
AID404065Antiviral activity against HSV1 infected in human primary amnion cells assessed as inhibition of virus-induced pathogenic effect1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID403986Antiviral activity against Sindbis virus in mouse 3T3-L1 cells at 250 nM1998Journal of natural products, Nov, Volume: 61, Issue:11
Antiviral activity of lignans.
AID400479Antiviral activity against measles virus infected in african green monkey Vero cells assessed as cell rounding at 1 uM
AID337694Antibacterial activity against Bacillus subtilis ATCC 6633 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (62.50)18.7374
1990's3 (18.75)18.2507
2000's2 (12.50)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.20 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]